Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of VALBIOTIS S.A. EO -,10
No Price
Closing Price XPAR 30.04.2026:
0,93 EUR
30.04.2026 15:35
Current Prices from VALBIOTIS S.A. EO -,10
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Paris
ALVAL.PA
EUR
30.04.2026 15:35
0,93 EUR
-0,005 EUR
-0,54 %
Düsseldorf
VSAAPE51.DUSB
EUR
30.04.2026 06:13
0,91 EUR
-
Quotrix
VSAAPE51.DUSD
EUR
30.04.2026 05:27
0,93 EUR
-
Share Float & Liquidity
Free Float95,91 %
Shares Float22,69 M
Shares Outstanding23,66 M
Company Profile for VALBIOTIS S.A. EO -,10 Share
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
